- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04939883
Carvediol이 Anthracycline 요법을 받은 암 환자의 심독성에 미치는 영향 (CardioTox)
안트라사이클린 요법을 받은 암 환자의 심독성에 대한 카르베딜롤의 효과를 평가하기 위한 전향적 다기관 무작위 연구
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%). Despite the high mortality rate of neoplasia, oncological treatment have advanced substantially in recent decades improving the prognosis of patients. However, growing evidence suggest that some oncological agents may induce significant toxicity that may play a major role in the quality of life, morbidity and mortality. The cardiovascular system is often negatively affected with cancer therapy, predisposing several patients to stop appropriate treatments or to have cardiovascular events related to the cardiotoxicity. The most typical manifestation of cardiotoxicity and related consequences (heart failure) are related to the use of anthracyclines. Anthracyclines are part of the chemotherapy regimen for solid tumors and hematological neoplasms in children and adults, and are associated with an increase in life expectancy. Carvedilol is an α and β-blocker that also has antioxidant properties. Preliminary studies have shown that carvedilol and its metabolites prevent lipid peroxidation, inhibit the formation and inactivate free radicals, in addition to preventing the depletion of endogenous antioxidants, such as vitamin E. These effects would potentially prevent anthracycline injury but definitive evidence is still needed. This is a multi-center, double-blind, randomized, placebo-controlled study that aims to establish the efficacy of carvedilol for the primary prevention of left ventricular systolic dysfunction in cancer patients obtained with anthracycline chemotherapy, in different schedules and doses.
연구 개요
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
São Paulo
-
São Paulo, São Paulo, 브라질, 01308-050
- Hospital Sirio Libanes
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- ≥18 years of age at the time of screening
- Cancer patients that will receive chemotherapy with anthracyclines.
Exclusion Criteria:
- Inability to adequate asses left ventricular function
- Previous symptoms (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and pulmonary and systemic congestion) suggestive of or a previous diagnosis of heart failure.
- Previous history of any cardiomyopathy (eg.: valve disease, Chagas' disease, infiltrative cardiomyopathy)
- LVEF < 50%
- Previous history of myocardial revascularization
- Permanent tachyarrhythmia (flutter, atrial fibrillation, atrial tachycardia)
- Congenital heart disease with left ventricular function impared
- Contra-indication to the use of beta-blockers.
- Pregnant or Breast-feeding females or women of childbearing age who intend to became pregnant.
- On kidney replacement therapy
- ECOG >= 4 or Karnofsky <=30
- Advanced hepatic failure (C score Child-Pugh and MELD > 15);
- Previous use of anthracycline
- Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study
- Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Intervention Group
Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy. |
Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications |
|
위약 비교기: Control Group
Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy. |
Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Drop in ejection fraction within 12 months of starting treatment.
기간: 12 months
|
Drop in ejection fraction> 10% to values less than 50% of the left ventricle |
12 months
|
|
Cardiac events within 12 months of starting treatment.
기간: 12 months
|
Cardiac events such as death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias |
12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Drop in ejection fraction within 12 months.
기간: 12 months
|
Drop in ejection fraction greater than 10% and values less than 55% |
12 months
|
|
Reduction in myocardial strain in 12 months from the start of treatment.
기간: 12 months
|
Relative reduction of more than 15% in myocardial strain |
12 months
|
|
Diastolic dysfunction within 12 months
기간: 12 months
|
Development of diastolic dysfunction within 12 months |
12 months
|
|
Elevation of biomarkers during chemotherapy and up to 12 months of follow-up
기간: 12 months
|
Elevation of biomarkers (NT-pro BNP and troponin) during chemotherapy and up to 24 months of follow-up |
12 months
|
|
Quality of life (EuroQol-5D).
기간: 12 months
|
Quality of life measured by questionnaire in up to 12 months. |
12 months
|
|
Cardiovascular complications in 12 months.
기간: 12 months
|
Cardiovascular complications (death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias) in 24 months. |
12 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Diagnosis of neoplasia within 12 months.
기간: 12 months
|
Diagnosis of another neoplasia |
12 months
|
|
Progression of oncological disease within 12 months.
기간: 12 months
|
Progression of oncological disease |
12 months
|
|
Tumor recurrence within 12 months.
기간: 12 months.
|
Tumor recurrence |
12 months.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Renato H D. lopes, MD, PhD, Hospital Sirio-Libanes
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- AVAP-NG 989
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .